See more : Miura Co., Ltd. (6005.T) Income Statement Analysis – Financial Results
Complete financial analysis of NATCO Pharma Limited (NATCOPHARM.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NATCO Pharma Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Revathi Equipment Limited (REVATHI.NS) Income Statement Analysis – Financial Results
- Triton Development S.A. (TRI.WA) Income Statement Analysis – Financial Results
- Asetek A/S (ASTK.OL) Income Statement Analysis – Financial Results
- Svedbergs i Dalstorp AB (publ) (SVED-B.ST) Income Statement Analysis – Financial Results
- Imagion Biosystems Limited (IBX.AX) Income Statement Analysis – Financial Results
NATCO Pharma Limited (NATCOPHARM.NS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.natcopharma.co.in
About NATCO Pharma Limited
NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina and CHF. The company markets its products in approximately 40 countries, including India, the United States, and internationally. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.02B | 27.07B | 19.05B | 16.90B | 18.88B | 20.62B | 21.57B | 20.40B | 11.25B | 8.19B | 7.31B | 6.50B | 5.20B | 4.37B | 4.31B | 4.38B | 3.28B | 2.42B | 1.68B | 1.54B |
| Cost of Revenue | 8.63B | 6.27B | 6.82B | 6.08B | 5.10B | 4.62B | 5.09B | 6.94B | 3.93B | 2.83B | 2.76B | 2.76B | 2.38B | 789.26M | 813.28M | 967.46M | 898.33M | 856.12M | 1.33B | 1.16B |
| Gross Profit | 31.40B | 20.80B | 12.23B | 10.82B | 13.78B | 16.00B | 16.48B | 13.46B | 7.32B | 5.35B | 4.55B | 3.74B | 2.82B | 3.58B | 3.49B | 3.41B | 2.38B | 1.56B | 355.49M | 388.24M |
| Gross Profit Ratio | 78.45% | 76.83% | 64.22% | 64.04% | 72.98% | 77.60% | 76.40% | 65.98% | 65.05% | 65.40% | 62.26% | 57.60% | 54.28% | 81.95% | 81.12% | 77.92% | 72.59% | 64.55% | 21.15% | 25.14% |
| Research & Development | 1.21B | 902.00M | 1.77B | 1.47B | 633.00M | 724.00M | 462.00M | 460.00M | 150.70M | 126.08M | 142.85M | 146.34M | 84.27M | 110.46M | 77.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.15B | 1.07B | 818.00M | 565.00M | 587.00M | 514.00M | 381.00M | 380.00M | 252.23M | 241.46M | 266.44M | 133.63M | 506.70M | 397.77M | 261.42M | 525.42M | 413.85M | 330.73M | 0.00 | 0.00 |
| Selling & Marketing | 1.53B | 961.00M | 437.00M | 344.00M | 981.00M | 1.37B | 1.37B | 1.43B | 1.13B | 373.58M | 261.60M | 148.21M | 225.27M | 132.42M | 125.58M | 55.89M | 43.20M | 32.86M | 0.00 | 0.00 |
| SG&A | 2.68B | 2.03B | 1.26B | 909.00M | 1.57B | 1.89B | 1.75B | 1.81B | 1.38B | 615.05M | 528.04M | 281.83M | 731.97M | 530.19M | 387.00M | 581.31M | 457.04M | 363.59M | 0.00 | 0.00 |
| Other Expenses | 1.28B | 1.05B | 40.00M | 110.00M | 40.00M | 20.00M | 16.00M | 11.00M | 18.15M | 14.19M | 14.15M | 4.00M | 5.01M | 2.05B | -3.42M | -35.77M | -11.05M | -18.09M | 116.58M | 71.29M |
| Operating Expenses | 31.16B | 13.08B | 10.81B | 5.81B | 8.87B | 8.82B | 7.72B | 6.90B | 4.95B | 3.65B | 3.04B | 2.43B | 1.89B | 2.69B | 2.64B | 2.65B | 1.72B | 1.06B | 116.58M | 71.29M |
| Cost & Expenses | 14.06B | 19.35B | 17.63B | 11.89B | 13.97B | 13.44B | 12.81B | 13.84B | 8.89B | 6.48B | 5.80B | 5.18B | 4.26B | 3.48B | 3.45B | 3.62B | 2.61B | 1.91B | 1.44B | 1.23B |
| Interest Income | 1.01B | 512.00M | 390.00M | 566.00M | 791.00M | 898.00M | 249.00M | 79.00M | 53.01M | 6.56M | 25.02M | 23.51M | 24.87M | 2.21M | -16.55M | -13.13M | 0.00 | 0.00 | 131.80M | 6.64M |
| Interest Expense | 192.00M | 145.00M | 132.00M | 88.00M | 177.00M | 162.00M | 132.00M | 160.00M | 212.17M | 302.93M | 343.13M | 249.46M | 230.36M | 141.98M | 130.37M | 137.95M | 85.05M | 56.88M | 69.64M | 125.27M |
| Depreciation & Amortization | 1.87B | 1.64B | 1.43B | 1.17B | 998.00M | 810.00M | 662.00M | 544.00M | 509.53M | 472.66M | 304.43M | 221.22M | 159.08M | 158.82M | 211.50M | 140.58M | 89.97M | 77.90M | 66.65M | 58.42M |
| EBITDA | 18.80B | 10.40B | 3.63B | 7.10B | 6.90B | 9.25B | 9.69B | 6.97B | 2.68B | 2.13B | 1.96B | 1.51B | 1.17B | 934.94M | 1.07B | 914.64M | 753.99M | 581.17M | 501.30M | 425.57M |
| EBITDA Ratio | 46.96% | 38.42% | 17.53% | 40.53% | 35.78% | 44.16% | 44.96% | 35.35% | 25.65% | 27.43% | 26.51% | 24.71% | 21.66% | 26.33% | 26.60% | 21.05% | 23.46% | 25.32% | 25.78% | 27.56% |
| Operating Income | 25.96B | 8.76B | 2.20B | 5.01B | 4.91B | 7.18B | 8.76B | 6.56B | 2.36B | 1.71B | 1.51B | 1.32B | 937.56M | 893.12M | 858.07M | 760.95M | 664.03M | 503.27M | 238.91M | 316.95M |
| Operating Income Ratio | 64.87% | 32.37% | 11.54% | 29.64% | 26.02% | 34.82% | 40.59% | 32.13% | 21.01% | 20.86% | 20.61% | 20.29% | 18.03% | 20.42% | 19.92% | 17.37% | 20.26% | 20.84% | 14.21% | 20.53% |
| Total Other Income/Expenses | -9.23B | -6.30B | -4.91B | -3.52B | 775.00M | -2.54B | 117.00M | -311.00M | -295.00M | -372.09M | -216.09M | -296.00M | -155.84M | -215.52M | -226.51M | -194.54M | -100.10M | -105.35M | 33.25M | -309.45M |
| Income Before Tax | 16.74B | 8.62B | 2.02B | 5.80B | 5.69B | 8.25B | 8.87B | 6.24B | 2.07B | 1.34B | 1.29B | 1.02B | 795.42M | 651.23M | 631.56M | 566.41M | 553.18M | 397.91M | 272.17M | 7.50M |
| Income Before Tax Ratio | 41.82% | 31.84% | 10.61% | 34.29% | 30.13% | 40.00% | 41.14% | 30.61% | 18.37% | 16.40% | 17.65% | 15.74% | 15.30% | 14.89% | 14.66% | 12.93% | 16.88% | 16.48% | 16.19% | 0.49% |
| Income Tax Expense | 2.85B | 1.47B | 322.00M | 1.37B | 1.11B | 1.82B | 1.92B | 1.40B | 527.98M | 39.50M | 308.70M | 364.36M | 210.75M | 132.11M | 136.61M | 112.90M | 148.04M | 93.29M | 34.23M | -8.07M |
| Net Income | 13.88B | 7.15B | 1.70B | 4.41B | 4.61B | 6.44B | 6.96B | 4.86B | 1.55B | 1.35B | 1.03B | 718.69M | 596.08M | 535.11M | 487.18M | 439.72M | 405.14M | 304.63M | 237.93M | 15.57M |
| Net Income Ratio | 34.69% | 26.42% | 8.92% | 26.08% | 24.41% | 31.25% | 32.28% | 23.82% | 13.80% | 16.44% | 14.06% | 11.06% | 11.46% | 12.23% | 11.31% | 10.03% | 12.36% | 12.61% | 14.16% | 1.01% |
| EPS | 77.34 | 39.18 | 9.32 | 24.20 | 25.33 | 34.98 | 39.26 | 27.89 | 9.14 | 8.13 | 6.43 | 4.60 | 4.11 | 3.80 | 3.46 | 3.14 | 2.89 | 2.20 | 1.75 | 0.12 |
| EPS Diluted | 77.34 | 39.18 | 9.32 | 24.16 | 25.26 | 34.87 | 39.13 | 27.87 | 9.11 | 8.13 | 6.43 | 4.58 | 4.11 | 3.80 | 3.46 | 3.14 | 2.89 | 2.20 | 1.75 | 0.12 |
| Weighted Avg Shares Out | 179.51M | 182.55M | 182.37M | 182.16M | 181.93M | 184.21M | 177.31M | 174.23M | 170.45M | 165.60M | 159.73M | 156.18M | 145.21M | 140.74M | 140.62M | 140.20M | 140.20M | 138.22M | 135.87M | 130.81M |
| Weighted Avg Shares Out (Dil) | 179.50M | 182.55M | 182.41M | 182.49M | 182.46M | 184.78M | 177.94M | 174.41M | 170.96M | 165.60M | 159.73M | 156.85M | 145.21M | 140.74M | 140.74M | 140.20M | 140.20M | 138.22M | 135.87M | 134.21M |
Source: https://incomestatements.info
Category: Stock Reports